Tags

Type your tag names separated by a space and hit enter

Tadalafil - a therapeutic option in the management of BPH-LUTS.
Int J Clin Pract. 2014 Jan; 68(1):94-103.IJ

Abstract

BACKGROUND/AIMS

Men with signs of benign prostatic hyperplasia (BPH) may experience lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, intermittence, nocturia, straining, incomplete emptying or a weak urinary stream. The effective management of LUTS suggestive of BPH (BPH-LUTS) requires careful consideration of several factors, including the severity of a patient's symptoms, concurrent or other coexisting medical conditions, the ability to improve symptoms and impact quality of life (QOL), as well as the potential side effects of available treatment options. Several clinical studies have assessed phosphodiesterase type 5 (PDE5) inhibitors in reducing LUTS; however, tadalafil is the only PDE5 inhibitor approved for the treatment of signs and symptoms of BPH, as well as in men with both erectile dysfunction (ED) and the signs and symptoms of BPH. This review examined articles that assessed tadalafil in patients with signs and symptoms of BPH, with or without erectile dysfunction (ED), which led to regulatory approval in the United States and Europe.

RESULTS

In dose-ranging and confirmatory studies, results demonstrate that tadalafil significantly improved total International Prostate Symptom Score (IPSS) following 12 weeks of treatment with once daily tadalafil 5 mg. Statistically significant improvements in Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS QOL and International Index of Erectile Function (IIEF) were also observed. Improvement in urinary symptoms occurred regardless of age, previous treatment with an α1 -adrenergic blocker, BPH-LUTS severity at baseline or ED status.

CONCLUSIONS

While tadalafil is most frequently recognised as a standard treatment option for men with ED, it also represents a well-tolerated and effective treatment option in men with moderate to severe BPH-LUTS.

Authors+Show Affiliations

University of North Carolina, Chapel Hill, NC, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24341303

Citation

Carson, C C., et al. "Tadalafil - a Therapeutic Option in the Management of BPH-LUTS." International Journal of Clinical Practice, vol. 68, no. 1, 2014, pp. 94-103.
Carson CC, Rosenberg M, Kissel J, et al. Tadalafil - a therapeutic option in the management of BPH-LUTS. Int J Clin Pract. 2014;68(1):94-103.
Carson, C. C., Rosenberg, M., Kissel, J., & Wong, D. G. (2014). Tadalafil - a therapeutic option in the management of BPH-LUTS. International Journal of Clinical Practice, 68(1), 94-103. https://doi.org/10.1111/ijcp.12305
Carson CC, et al. Tadalafil - a Therapeutic Option in the Management of BPH-LUTS. Int J Clin Pract. 2014;68(1):94-103. PubMed PMID: 24341303.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tadalafil - a therapeutic option in the management of BPH-LUTS. AU - Carson,C C, AU - Rosenberg,M, AU - Kissel,J, AU - Wong,D G, PY - 2013/06/19/received PY - 2013/08/23/accepted PY - 2013/12/18/entrez PY - 2013/12/18/pubmed PY - 2015/4/4/medline SP - 94 EP - 103 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 68 IS - 1 N2 - BACKGROUND/AIMS: Men with signs of benign prostatic hyperplasia (BPH) may experience lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, intermittence, nocturia, straining, incomplete emptying or a weak urinary stream. The effective management of LUTS suggestive of BPH (BPH-LUTS) requires careful consideration of several factors, including the severity of a patient's symptoms, concurrent or other coexisting medical conditions, the ability to improve symptoms and impact quality of life (QOL), as well as the potential side effects of available treatment options. Several clinical studies have assessed phosphodiesterase type 5 (PDE5) inhibitors in reducing LUTS; however, tadalafil is the only PDE5 inhibitor approved for the treatment of signs and symptoms of BPH, as well as in men with both erectile dysfunction (ED) and the signs and symptoms of BPH. This review examined articles that assessed tadalafil in patients with signs and symptoms of BPH, with or without erectile dysfunction (ED), which led to regulatory approval in the United States and Europe. RESULTS: In dose-ranging and confirmatory studies, results demonstrate that tadalafil significantly improved total International Prostate Symptom Score (IPSS) following 12 weeks of treatment with once daily tadalafil 5 mg. Statistically significant improvements in Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS QOL and International Index of Erectile Function (IIEF) were also observed. Improvement in urinary symptoms occurred regardless of age, previous treatment with an α1 -adrenergic blocker, BPH-LUTS severity at baseline or ED status. CONCLUSIONS: While tadalafil is most frequently recognised as a standard treatment option for men with ED, it also represents a well-tolerated and effective treatment option in men with moderate to severe BPH-LUTS. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/24341303/Tadalafil___a_therapeutic_option_in_the_management_of_BPH_LUTS_ L2 - https://doi.org/10.1111/ijcp.12305 DB - PRIME DP - Unbound Medicine ER -